Fellows' Journal Club


In this conference, fellows identify a specific question to be answered and present practice-changing articles that helped to fill this gap in knowledge. The articles need not have been published recently but should be recognized as landmarks in each area.

Citations and abstracts

Citations and abstracts of articles discussed can be viewed by clicking the PubMed link.


Monthly (4th Wednesday, unless noted otherwise)
12:00-1:00 PM
11th Floor North Conference Room, Mid-Campus Center

2017-2018 Academic Year

Date Speaker Title Link
Aug 30, 2017 Bita Fakhri Hodgkin's Lymphoma
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
  Eric Huselton Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma PubMed
  Nancy Bartlett
Faculty Discussant
Fine-Tuning the Treatment of Hodgkin's Lymphoma PubMed
Sep 27, 2017 Natasha Edwin Acute Myeloid Leukemia
Midostaurin Plus Chemotherapy for Acute Myeloid Leukemia With a FLT3 Mutation
  Ramzi Abboud Enasidenib in Mutant IDH2 Relapsed or Refractory Acute Myeloid Leukemia PubMed
  Geoff Uy
Faculty Discussant
Oct 26, 2017
Amber Xu Breast Cancer
Olaparib for Metastatic Breast Cancer in Patients With a Germline BRCA Mutation
  Aabha Oza Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer PubMed
  Ashley Frith
Faculty Discussant
Nov 29, 2017 Amber Xu Lower GI
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
  Miriam Jacobs Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer PubMed
  Haeseong Park
Faculty Discussant
Dec 20, 2017 Ramon Jin Upper GI
Trastuzumab in Combination With Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial
  Amber Afzal Regorafenib for Patients With Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial PubMed
  Andrea Wang-Gillam
Faculty Discussant
Jan 24, 2018 Daniel Guy MPN/CML
Ponatinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukaemia: An International, Randomised, Open-Label, Phase 3 Trial
  Amber Afzal JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis PubMed
  Amy Zhou
Faculty Discussant
Feb 21, 2018 Stephen Barman Lung
Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
  Nkiruka Ezenwajiaku Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer PubMed
  Sid Devarakonda
Faculty Discussant
Mar 21, 2018 Nkiruka Ezenwajiaku Genitourinary
Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
  Patrick Grierson Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma PubMed
  Joel Picus
Faculty Discussant
Apr 18, 2018 Nusayba Bagegni Benign Hematology
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
  Pavan Bhamidipati Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura PubMed
  Elaine Majerus
Faculty Discussant
May 2, 2018 Francesca Ferraro Thrombosis/Anticoagulation
May 30, 2018 Patrick Grierson Melanoma
  Aabha Oza
Jun 13, 2018 Bruna Pellini Ferreira Primary Gliomas
Jun 20, 2018 Brett Herzog Brain Metastases